ArticleJournal of biomedical materials research. Part A2012
In situ crosslinkable heparin-containing poly(ethylene glycol) hydrogels for sustained anticoagulant release.
Article in Journal of biomedical materials research. Part A, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 51 citations in OpenAlex.
- 3D Printing as a Strategy to Scale-Up Biohybrid Hydrogels for T Cell Manufacture.ACS applied materials & interfaces · 2024Article
- Biopolymer-Based Nanogel Approach in Drug Delivery: Basic Concept and Current Developments.Pharmaceutics · 2023Review
- Bioprinting Technologies and Bioinks for Vascular Model Establishment.International journal of molecular sciences · 2023Review
- Fast-Forming Dissolvable Redox-Responsive Hydrogels: Exploiting the Orthogonality of Thiol-Maleimide and Thiol-Disulfide Exchange Chemistry.Biomacromolecules · 2022Article
- Redox-Responsive Hydrogels for Tunable and "On-Demand" Release of Biomacromolecules.Bioconjugate chemistry · 2022Article
- Nanohydrogels: Advanced Polymeric Nanomaterials in the Era of Nanotechnology for Robust Functionalization and Cumulative Applications.International journal of molecular sciences · 2022Review
- Thrombolytic Agents: Nanocarriers in Controlled Release.Small (Weinheim an der Bergstrasse, Germany) · 2020Review
- Low-Molecular-Weight Heparins: Reduced Size Particulate Systems for Improved Therapeutic Outcomes.Molecules (Basel, Switzerland) · 2018Review
- Controlling the Release of Small, Bioactive Proteins via Dual Mechanisms with Therapeutic Potential.Advanced healthcare materials · 2017Article
- Passive targeting and lung tolerability of enoxaparin microspheres for a sustained antithrombotic activity in rats.Drug delivery · 2017Article
- Reduced arterial elasticity due to surgical skeletonization is ameliorated by abluminal PEG hydrogel.Bioengineering & translational medicine · 2017Article
- Responsive Hybrid (Poly)peptide-Polymer Conjugates.Journal of materials chemistry. B · 2017Article
- Thiol-ene click hydrogels for therapeutic delivery.ACS biomaterials science & engineering · 2016Article
- Liposome-Cross-Linked Hybrid Hydrogels for Glutathione-Triggered Delivery of Multiple Cargo Molecules.Biomacromolecules · 2016Article
- Poly(ethylene glycol) (PEG)-lactic acid nanocarrier-based degradable hydrogels for restoring the vaginal microenvironment.Journal of controlled release : official journal of the Controlled Release Society · 2014Article
- Self-titrating anticoagulant nanocomplexes that restore homeostatic regulation of the coagulation cascade.ACS nano · 2014Article
- Heparin-functionalized polymeric biomaterials in tissue engineering and drug delivery applications.Acta biomaterialia · 2014Review
- Designing degradable hydrogels for orthogonal control of cell microenvironments.Chemical Society reviews · 2013Review
- Reversible maleimide-thiol adducts yield glutathione-sensitive poly(ethylene glycol)-heparin hydrogels.Polymer chemistry · 2013Article
- Advances in hydrogels for capturing and neutralizing inflammatory cytokines.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Low-molecular weight heparin (LMWH) is widely used in anticoagulation therapies and for the prevention of thrombosis. LMWH is administered by subcutaneous injection usually once or twice per day. This frequent and invasive delivery modality leads to compliance issues for individuals on prolonged therapeutic courses, particularly pediatric patients. Here, we report a long-term delivery method for LMWH via subcutaneous injection of long-lasting hydrogels. LMWH is modified with reactive maleimide groups so that it can be crosslinked into continuous networks with four-arm thiolated poly(ethylene glycol) (PEG-SH). Maleimide-modified LMWH (Mal-LMWH) retains bioactivity as indicated by prolonged coagulation time. Hydrogels comprising PEG-SH and Mal-LMWH degrade via hydrolysis, releasing bioactive LMWH by first-order kinetics with little initial burst release. Separately dissolved Mal-LMWH and PEG-SH solutions were co-injected subcutaneously in New Zealand White rabbits. The injected solutions successfully formed hydrogels in situ and released LMWH as measured via chromogenic assays on plasma samples, with accumulation of LMWH occurring at day 2 and rising to near-therapeutic dose equivalency by day 5. These results demonstrate the feasibility of using LMWH-containing, crosslinked hydrogels for sustained and controlled release of anticoagulants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.